ConductScience.org, home

Paper7227366

Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Chou TC and 1 other. Eur J Biochem, 1981. Cited by 370 papers, by iCite.

Cite this record

ConductScience Library. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Papers, record 7227366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7227366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.
PubMed
Journal
Eur J Biochem
PubMed
Year
1981
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
370
iCite
Relative citation ratio, by iCite
8.63
iCite
Revised in PubMed
2019-06-20
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chou TCT C
2Talalay PP

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Enzyme InhibitorsMajor topic
Kinetics
Mathematics
Models, Biological

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
AM 07422NIADDK NIH HHSUnited StatesPubMedPubMed
CA 27569NCI NIH HHSUnited StatesR01CA027569PubMed and NIHNIH RePORTER
GM 16492NIGMS NIH HHSUnited StatesPubMedPubMed

Download CSV of grants

Cited by173

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 370 citations.

PMIDTitleJournalYearIn PapersSource
42003968Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib.Front Oncol2026https://conductscience.org/library/papers/42003968PubMed
41027874Challenges to determine synergistic drug interactions in mice.Nat Commun2025https://conductscience.org/library/papers/41027874PubMed
40341222Synergistic effects of abietic acid combined with doxorubicin on apoptosis induction in a human colorectal cancer cell line.Sci Rep2025https://conductscience.org/library/papers/40341222PubMed
39802605Gossypol enhances ponatinib's cytotoxicity against human hepatocellular carcinoma cells by involving cell cycle arrest, p-AKT/LC3II/p62, and Bcl2/caspase-3 pathways.Toxicol Rep2025https://conductscience.org/library/papers/39802605PubMed
39791794Multifunctional Nanoparticles as Radiosensitizers to Overcome Hypoxia-Associated Resistance in Cancer Radiotherapy.Nanomaterials (Basel)2024https://conductscience.org/library/papers/39791794PubMed
39627385Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis.Acta Pharmacol Sin2025https://conductscience.org/library/papers/39627385PubMed
39456799Synergistic Proliferation Effects of Xanthohumol and Niflumic Acid on Merkel and Glioblastoma Cancer Cells: Role of Cell Membrane Interactions.Int J Mol Sci2024https://conductscience.org/library/papers/39456799PubMed
38236451Synergistic effect of a nonsteroidal anti-inflammatory drug in combination with topotecan on small cell lung cancer cells.Mol Biol Rep2024https://conductscience.org/library/papers/38236451PubMed
38132957The Salmon Oil OmeGo Reduces Viability of Colorectal Cancer Cells and Potentiates the Anti-Cancer Effect of 5-FU.Mar Drugs2023https://conductscience.org/library/papers/38132957PubMed
37232374Anti‑metastatic activity of aromatic aminomethylidenebisphosphonates in a mouse model of 4T1 cell‑derived breast cancer.Oncol Rep2023https://conductscience.org/library/papers/37232374PubMed
37121274High-throughput approaches to uncover synergistic drug combinations in leukemia.SLAS Discov2023https://conductscience.org/library/papers/37121274PubMed
36662193Gold Nanoparticles Synthesized by an Aqueous Extract of Codium tomentosum as Potential Antitumoral Enhancers of Gemcitabine.Mar Drugs2022https://conductscience.org/library/papers/36662193PubMed
36185647A network pharmacology approach to evaluate the synergistic effect of dihydromyricetin and myricitrin in vine tea on the proliferation of B16F10 cells.Front Nutr2022https://conductscience.org/library/papers/36185647PubMed
35986755Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones.Arch Toxicol2022https://conductscience.org/library/papers/35986755PubMed
35983428
Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Drug Des Devel Ther2022https://conductscience.org/library/papers/35983428PubMed
35890123Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/35890123PubMed
35440025CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.BMC Cancer2022https://conductscience.org/library/papers/35440025PubMed
34991440Non-parametric synergy modeling of chemical compounds with Gaussian processes.BMC Bioinformatics2022https://conductscience.org/library/papers/34991440PubMed
34637097Quercetin potentiates the chemosensitivity of MCF-7 breast cancer cells to 5-fluorouracil.Mol Biol Rep2021https://conductscience.org/library/papers/34637097PubMed
34386644Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells.Dev Reprod2021https://conductscience.org/library/papers/34386644PubMed

See all 173 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7227366

GET https://conductscience.org/api/papers/v1/7227366/cited_by?page=2